ACM
ABBV icon

Atika Capital Management’s AbbVie ABBV Stock Holding History

Atika Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$10.7M – 91
2020
Q4 		$10.7M Buy
+100,000
New +$9.61M 0.84% 57
2018
Q1 		– Sell
-60,000
Closed -$5.8M – 72
2017
Q4 		$5.8M Hold
60,000
– – 2.24% 12
2017
Q3 		$5.33M Buy
+60,000
New +$4.57M 1.53% 12

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atika Capital Management's ABBV Position: Q2 2018 in Review

Atika Capital Management sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 25,000 shares — an estimated $2.37M sold.

Atika Capital Management first reported a position in ABBV in Q2 2014 and held it in 5 quarters. The position peaked at $4.16M in Q3 2014. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

  • Atika Capital Management reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
  • Atika Capital Management sold 25,000 AbbVie shares in Q2 2018, an estimated $2.37M.
  • Atika Capital Management first reported a position in AbbVie in Q2 2014 and held it in 5 quarters.
  • Atika Capital Management's AbbVie position peaked at $4.16M in Q3 2014.
  • 1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Atika Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.